证券代码：300261 证券简称：雅本化学 公告编号：2025-035 雅本化学股份有限公司 关于提请股东大会授权董事会办理 以简易程序向特定对象发行股票相关事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 雅本化学股份有限公司（以下简称"公司"）于2025年4月21日召开第六届董事 会第二次会议和第六届监事会第二次会议审议通过了《关于提请股东大会授权董事 会办理以简易程序向特定对象发行股票相关事宜的议案》。该议案尚需提交2024年 年度股东大会审议。 一、本次授权事项概述 授权董事会根据《中华人民共和国公司法》《中华人民共和国证券法》《上公司 证券发行注册管理办法（2025 年修正）》等有关法律法规和规范性文件的规定，对 公司实际情况及相关事项进行自查和论证，确认公司是否符合以简易程序向特定对 象发行股票的条件。 （二）发行股票的种类、面值和数量 本次发行股票的种类为境内上市的人民币普通股（A 股），每股面值人民币 1.00 元。发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，发 行的股票数量按照募集资金总额除以发行价格确 ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-041 雅本化学股份有限公司 关于召开2024年年度股东大会通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据雅本化学股份有限公司（以下简称"公司"）第六届董事会第二次会议 的决定，公司将于 2025 年 5 月 13 日召开公司 2024 年年度股东大会，现将有关 事项通知如下： 一、本次会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：经公司第六届董事会第二次会议审议通过， 决定召开 2024 年年度股东大会，召集程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 4、会议召开的日期、时间 现场会议时间：2025 年 5 月 13 日（星期二）下午 14:30 网络投票时间：2025 年 5 月 13 日 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 13 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00； 通过深圳证券交易所互联网系统投 ...

经审核，监事会认为：公司 2024 年年度报告的审议程序符合法律法规和中国证 监会的有关规定，2024 年年度报告的内容真实、准确、完整地反映了公司 2024 年 年度经营的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。详见中国 证监会指定信息披露网站刊登的公告。 雅本化学股份有限公司 证券代码：300261 证券简称：雅本化学 公告编号：2025-032 第六届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司（以下简称"公司"）第六届监事会第二次会议于 2025 年 4 月 21 日上午 11:30 以现场结合通讯方式召开。会议通知已于 2025 年 4 月 11 日 以邮件方式送达全体监事。本次会议应到监事 3 人，实到 3 人。本次会议由监事会主 席黄亮先生主持。本次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的监事充分讨论与审议，会议形成以下决 议： 1. 审议并通过《关于<2024 年年度报告>及其摘要的议案》 表决结果：赞成3票，反对0票，弃 ...

雅本化学股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司(以下简称"公司")第六届董事会第二次会议于 2025 年 4 月 21 日上午 10:00 以现场结合通讯方式召开，会议通知已于 2025 年 4 月 11 日以 邮件方式送达全体董事和监事。本次会议应出席董事 8 名，实际出席会议董事 8 名。 会议由公司董事长兼总经理蔡彤先生主持，公司部分监事及高级管理人员列席了会 议。本次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 证券代码：300261 证券简称：雅本化学 公告编号：2025-031 1. 审议并通过《关于<2024 年年度报告>及其摘要的议案》 经审议，董事会认为公司严格按照相关法律法规的规定，编制了 2024 年年度报 告及其摘要，报告真实、准确、完整地反映了公司 2024 年度的财务状况和经营成果， 不存在虚假记载、误导性陈述和重大遗漏。详见中国证监会指定信息披露网站刊登 的公告 ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-033 雅本化学股份有限公司 关于2024年度拟不进行利润分配的专项说明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 1、公司 2024 年度利润分配预案为：不进行现金分红、不送红股、不以资本公 积转增股本。 2、公司利润分配预案不触及《深圳证券交易所创业板股票上市规则》第9.4条 第（八）项规定的可能被实施其他风险警示情形。 一、审议程序 雅本化学股份有限公司（以下简称"公司"）于2025年4月21日召开第六届董事 会第二次会议及第六届监事会第二次会议审议通过了《关于公司2024年度利润分配 方案的议案》，该议案尚需提交公司2024年年度股东大会审议。 二、2024年度利润分配预案 经众华会计师事务所（特殊普通合伙）为公司出具的标准无保留意见审计报告 确认，2024年度公司实现营业收入120,217.88万元，较上年同期下降6.00%；实现归 属于上市公司股东的净利润-25,770.27万元，比上年同期下降213.15%。截至2024年 12月31日，合并报表未分配利润为2 ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-034 雅本化学股份有限公司 关于 2023 年员工持股计划首次受让部分及预留受让部分 第一个锁定期解锁条件未成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司(以下简称"公司")于 2025 年 4 月 21 日召开了第六届 董事会第二次会议和第六届监事会第二次会议，审议通过了《关于 2023 年员工持股 计划首次受让部分及预留受让部分第一个锁定期解锁条件未成就的议案》。根据《雅 本化学股份有限公司 2023 年员工持股计划（草案修订稿）》（以下简称"《2023 年员工持股计划》"或"本员工持股计划"）《雅本化学股份有限公司关于 2023 年员工持股计划预留份额分配的公告》（以下简称"《预留份额分配公告》"）的 相关规定，本员工持股计划首次受让部分及预留受让部分第一个锁定期解锁条件未 成就，对应未解锁的权益份额不得解锁。现将相关事项公告如下： 一、本员工持股计划批准及实施情况 （一）2023年8月24日，公司召开了第五届董事会第十一次会议和第五届监事会 第十次会议 ...

Financial Performance - The company reported a net profit attributable to shareholders of -257.70 million RMB for the year 2024, indicating a significant decline compared to the previous year due to product price fluctuations and intensified market competition [4]. - The company's operating revenue for 2024 was ¥1,202,178,750.59, a decrease of 6.00% compared to ¥1,278,848,252.00 in 2023 [19]. - The net profit attributable to shareholders for 2024 was -¥257,702,742.43, representing a decline of 213.15% from -¥82,293,808.08 in 2023 [19]. - The company's operating profit was CNY -30,815.19 million, down 292.50% year-on-year, and the total profit was CNY -30,890.67 million, a decline of 247.79% [52]. - The net profit attributable to the parent company was CNY -25,770.27 million, representing a decrease of 213.15% compared to the previous year [52]. - The company reported a significant increase in the sales of chemical products, with operating revenue after deductions amounting to ¥1,168,285,996.89 in 2024 [20]. - The company faced challenges in the pesticide industry, with global market growth from $35.575 billion in 2006 to $87.7 billion in 2022, reflecting a compound annual growth rate of approximately 5.80% [29]. - The company reported a total revenue of 2.55 billion in the latest financial period, reflecting a growth of 10.5% compared to the previous year [146]. Dividend and Capital Management - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves for the year [7]. - The company plans to distribute cash dividends of RMB 0.5 per 10 shares, totaling a cash dividend of RMB 481,654.74, which is 0.00% of the total profit distribution [168]. - The company has no plans for cash dividends, stock bonuses, or capital reserve transfers for the 2024 profit distribution [170]. - The company raised a total of RMB 867,109,999.04 through a non-public offering of 105,231,796 shares, with a net amount of RMB 847,613,986.89 after deducting issuance fees [92]. Research and Development - The company has invested significantly in R&D, leading to strong technical advantages and cost efficiencies in the production of its pesticide intermediates [40]. - R&D expenses increased by 2.71% to CNY 12,327.90 million, reflecting the company's commitment to innovation [52]. - The company is focusing on technological innovations in continuous manufacturing and AI-assisted drug design to enhance global competitiveness [32]. - The company is committed to continuous innovation in R&D, focusing on green chemistry processes and continuous flow technology to improve production efficiency and reduce environmental impact [118]. Market and Competitive Landscape - The company's operational performance is under pressure from multiple factors, including market competition and product pricing [4]. - The company noted that despite a competitive market, domestic pesticide production is expected to gain strength with increasing approvals for new pesticide formulations [30]. - The company is actively pursuing certifications such as GMP compliance and Halal certifications to enhance its marketability and compliance [39]. - The company is targeting significant market demand for its new pesticide products, indicating a strong growth potential in the agricultural sector [40]. Environmental and Sustainability Efforts - The company is committed to environmental management and has obtained various environmental certifications, including ISO 14001 [39]. - The company has established comprehensive waste treatment facilities to minimize environmental impact during production activities [179]. - The company has implemented a sustainable procurement system and conducting annual assessments of suppliers to ensure alignment with business needs [120]. - The company is focused on ESG governance, aiming to improve management efficiency and reduce carbon emissions in line with SBTi commitments [121]. Governance and Compliance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements [133]. - The company maintains an independent financial department with a complete accounting system, allowing for independent financial decision-making and tax compliance [139]. - The company has established a governance structure that complies with relevant laws and regulations, with no unresolved governance issues [130]. - The company has implemented an employee stock ownership plan, with 53 employees holding a total of 6,400,000 shares, representing 0.90% of the company's total equity [170]. Operational Efficiency and Capacity - The designed capacity for pesticide intermediates and raw materials is 7,400 tons, with a utilization rate of 27.58% [36]. - The company is currently constructing additional capacity of 700 tons for pesticide intermediates and raw materials [36]. - The company has established six core production bases and two cooperative production bases, optimizing its supply chain and ensuring stable operations [45]. - The company has completed upgrades on certain production lines at the Taicang base, with a total investment of 37,032,000 RMB, achieving a 100% completion rate [100]. Risk Management - The company has detailed potential risks and countermeasures in the management discussion and analysis section of the report [6]. - The company is managing goodwill impairment risks from acquisitions by strengthening governance of subsidiaries and supporting their business development [124]. - The company is addressing potential risks from new project investments by conducting thorough market research and establishing a dedicated project management team [123]. - The company is monitoring exchange rate fluctuations and utilizing financial tools to mitigate risks associated with currency volatility [125].

证券代码：300261 证券简称：雅本化学 公告编号：2025-029 雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"） 第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》，为满足子公 司的经营发展需要，公司同意为兰州雅本精细化工有限公司（以下简称"兰雅 精化"）办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子公司提供担保及子公司互相担保的公 告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临时股 东大会审议通过了上述议案。 二、担保的进展情况 为满足日常经营发展需要，兰雅精化向交通银行股份有限公司甘肃省分行 （以下简称"交通银行甘肃省分行"）申请不超过人民币 1,000 万元的授信额 度。公司近日与交通银行甘肃省分行续签了《保证合同 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]